ArticleAnnals of medicine2026
Prognostic risk modeling based on integrated multi-omics analysis identifies CRY2 as a key regulator in tumor immunity and patient survival in colorectal cancer.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) exhibits substantial metabolic heterogeneity. This study developed a robust prognostic signature integrating ferroptosis- and lipid metabolism-related genes to investigate the role of CRY2 in CRC progression.
methodsTranscriptomic and clinical data from the TCGA-COAD and GSE39582 cohorts were analyzed. Weighted gene co-expression network analysis (WGCNA) was performed to identify disease-associated gene modules. A machine learning framework was subsequently applied to construct and optimize the prognostic model, with the combination of forward stepwise Cox regression (StepCox) and Random Survival Forest demonstrating the best predictive performance. The tumor immune microenvironment was characterized using CIBERSORT and TIDE. The biological function of CRY2 was validated through siRNA-mediated knockdown, functional assays, and a murine xenograft model.
resultsThe ferroptosis- and lipid metabolism-related RiskScore was identified as an independent predictor of overall survival (HR > 1.1,
conclusionThis study developed and validated a ferroptosis- and lipid metabolism-related prognostic signature that accurately predicts survival outcomes and immune characteristics in CRC. Furthermore, CRY2 was identified as a critical regulator of tumor growth.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.